Aims: This study aimed to investigate the clinical value of ¹²⁵I radioactive particle implantation combined with regional arterial chemotherapy perfusion in the treatment of pancreatic cancer.
Subjects and Methods: The clinical data of 23 patients with pancreatic cancer were retrospectively analyzed, and the patients were divided into two groups. In the observation group, 11 patients were injected with radioactive particles in combination with regional arterial chemotherapy. In the control group, 12 patients were treated with simple regional arterial perfusion chemotherapy. Curative effect, pain relief, survival period, and adverse reactions were compared between the two groups.
Results: The proportion of patients was significantly higher in the observation group (complete remission + partial remission) (72.73%) than in the control group (41.67%). The 6-month and 9-month survival rates in the experimental group were 91.7% and 50%, respectively, while those in the control group were 63.6% and 18.2%, respectively, with significantly statistical difference. The 12-month survival rate in the experimental group was 16.7% and was significantly higher than that in the control group (8.3%). The experimental group should greater improvement in pain symptoms than the control group, and there was no statistical difference between the two groups except in complications of ¹²⁵I radioactive particle implantation.
Conclusions: We conclude that ¹²⁵I radioactive particle implantation combined with regional arterial perfusion chemotherapy is an effective and comprehensive treatment for advanced pancreatic cancer.


中文翻译：

---

CT引导下125I粒子植入联合动脉灌注化疗治疗胰腺癌的临床疗效


目的：本研究旨在探讨¹²⁵ I放射性粒子植入联合局部动脉化疗灌注治疗胰腺癌的临床价值。
对象与方法：回顾性分析23例胰腺癌患者的临床资料，将患者分为两组。观察组11例患者注射放射性粒子联合局部动脉化疗。对照组12例接受单纯局部动脉灌注化疗。比较两组疗效、疼痛缓解情况、生存期及不良反应情况。
结果：观察组患者比例（完全缓解+部分缓解）（72.73%）明显高于对照组（41.67%）。实验组6个月和9个月生存率分别为91.7%和50%，而对照组分别为63.6%和18.2%，差异有统计学意义。实验组12个月生存率为16.7%，明显高于对照组（8.3%）。^{实验组疼痛症状改善较对照组大，除125} I放射性粒子植入并发症外，两组无统计学差异。
结论：我们得出的结论是¹²⁵I放射性粒子植入联合局部动脉灌注化疗是治疗晚期胰腺癌的有效综合治疗方法。